Condition (MeSH)
Anemia, Sideroblastic
ClinicalTrials.gov lists 2 trials for Anemia, Sideroblastic or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Anemia, Sideroblastic itself; the rest are tagged with a narrower condition beneath it.
When did Anemia, Sideroblastic trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2007 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Anemia, Sideroblastic trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Observational | 1 |
How many Anemia, Sideroblastic trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Anemia, Sideroblastic trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 1 |
Which serious adverse events do Anemia, Sideroblastic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Iron overload | 5 | 1 |
| Abdominal pain upper | 4 | 1 |
| Cholelithiasis | 4 | 1 |
| Acute tonsillitis | 3 | 1 |
| Appendicitis | 3 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Anemia, Sideroblastic? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. | American journal of hematology | 2023 | Yes |
| Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. | Leukemia | 2022 | Yes |
| Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. | The New England journal of medicine | 2020 | Yes |
| Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. | Annals of the rheumatic diseases | 2018 | Yes |
| SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. | Blood | 2015 | Yes |
Showing 5 of 15 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Sideroblastic anemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Sideroblastic anemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Sideroblastic anemia | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Sideroblastic anemia | 1047 | Exact | Orphadata Science knowledge files, Product 1 |
| Sideroblastic anemia | 1047 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.